Meis J M, Butler J J, Osborne B M, Ordóñez N G
Cancer. 1987 Apr 15;59(8):1475-85. doi: 10.1002/1097-0142(19870415)59:8<1475::aid-cncr2820590814>3.0.co;2-2.
Twenty-two patients with solitary plasmacytoma of bone (SPB) and 13 with extramedullary plasmacytomas (EMP) were studied. The average follow-up period for SPB was 90 months and 86 months for EMP. Thirty-six percent of patients with SPB developed multiple myeloma (MM) in an average of 39 months, and 23% of patients with EMP developed MM in an average of 23 months. No significant differences in survival, incidence of MM, or interval to the development of MM were found between the two groups. The 11 cases of EMP with evaluable tissue for immunohistochemical study were either monotypic kappa or lambda, as were 9 of 10 SPB. Presence of monoclonality did not predict the development of MM. The histologic parameters of nuclear immaturity and presence of prominent nucleoli seem to be the best indicators of which patients will develop MM. Solitary plasmacytoma of bone and EMP appear to be more closely related than has been previously recognized.
对22例骨孤立性浆细胞瘤（SPB）患者和13例髓外浆细胞瘤（EMP）患者进行了研究。SPB患者的平均随访期为90个月，EMP患者为86个月。36%的SPB患者平均在39个月后发展为多发性骨髓瘤（MM），23%的EMP患者平均在23个月后发展为MM。两组在生存率、MM发病率或发展为MM的间隔时间方面未发现显著差异。11例可进行免疫组织化学研究的EMP病例为单型κ或λ，10例SPB中有9例也是如此。单克隆性的存在并不能预测MM的发展。核不成熟和明显核仁的组织学参数似乎是哪些患者会发展为MM的最佳指标。骨孤立性浆细胞瘤和EMP似乎比之前认为的关系更密切。
